Advertisement
BIIB vs MRK
Which Stock Would AI Choose? Biogen (BIIB) vs. Merck & Co. (MRK) Stock Comparison
Key Takeaways
- BIIB (Biogen) is a focused neuroscience and rare-disease biotech, while MRK (Merck & Co.) is a diversified pharmaceutical giant spanning oncology, vaccines, and animal health.
- Both stocks have delivered strong year-to-date gains, but MRK has outperformed over the trailing year, while BIIB has shown stronger recent momentum.
- BIIB is pivoting through acquisitions and a late-stage immunology pipeline; MRK is preparing for the patent expiration of its flagship drug Keytruda.
- Valuations differ sharply, with MRK trading at a much higher price-to-earnings (P/E) multiple than BIIB.
- Risk profiles diverge: BIIB carries pipeline and clinical-trial risk, while MRK faces legal, generic-competition, and product-concentration risk.
Introduction
Investors weighing two healthcare names often compare a specialized biotech against a diversified pharmaceutical leader, and that is exactly the contrast between BIIB and MRK. Biogen concentrates on neurological and rare-disease therapies, while Merck operates across oncology, vaccines, cardiometabolic treatments, and animal health. This stock comparison is relevant for traders assessing relative performance and market positioning, as well as longer-term investors evaluating how each company is navigating patent cliffs, pipeline catalysts, and shifting sentiment. Understanding their different business models, growth drivers, and risk factors helps clarify which profile may better suit a given strategy in the current market environment.
BIIB Overview and Recent Performance
Biogen develops medicines for brain, nervous-system, and rare conditions, anchored by a multiple sclerosis (MS) franchise alongside products such as Spinraza and Leqembi. The company has been reshaping its portfolio, notably through its acquisition of Apellis Pharmaceuticals and the purchase of RayThera, while advancing immunology candidates such as litifilimab for lupus and felzartamab for antibody-mediated rejection after kidney transplant.
In recent market activity, BIIB has traded near its 52-week high, supported by a string of analyst upgrades and pipeline-focused optimism. The shares have gained roughly 30% year to date and more than 50% over the trailing year, though performance over three and five years remains negative, reflecting a longer turnaround. Sentiment has been lifted by a JPMorgan upgrade and raised price targets citing a catalyst path into 2027. At the same time, near-term earnings are expected to decline, and the MS franchise continues to face gradual erosion, keeping the outlook balanced.
MRK Overview and Recent Performance
Merck & Co. is a global healthcare company generating revenue across oncology, vaccines, cardiometabolic therapies, and animal health. Its portfolio is led by Keytruda, a blockbuster cancer immunotherapy, with additional franchises in HPV vaccines such as Gardasil and newer launches including Winrevair for pulmonary arterial hypertension. Merck has also pursued acquisitions, including Cidara Therapeutics and Terns Pharmaceuticals, while advancing a personalized mRNA cancer-vaccine program with Moderna.
Over recent months, MRK has posted substantial gains, up more than 40% year to date and roughly 79% over the trailing year, though the stock has pulled back modestly in recent weeks. Performance has been supported by strong Keytruda demand and pipeline momentum, while a Dutch court injunction limiting subcutaneous Keytruda in parts of Europe added a legal overhang. Merck also faces headwinds from Gardasil sales weakness in China and anticipated generic competition, even as investors weigh its dividend and longer-term pipeline breadth.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page offers a curated view of its AI-powered trading tools. Tickeron maintains hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only the most suitable for current market conditions earn a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance record, and set of tickers, so no two are alike. Because these bots are continuously evaluated against live market conditions, the list highlights those currently demonstrating the strongest alignment with prevailing trends. Explore the Trending AI Robots to see which automated strategies are drawing attention right now.
Head-to-Head Comparison
The clearest contrast between BIIB and MRK is scale and diversification. Merck generates roughly $66 billion in trailing revenue across multiple segments, while Biogen is far smaller at under $10 billion and remains heavily tied to neurology and rare disease. This gives Merck a broader revenue base but also exposes it to the 2028 loss of exclusivity on Keytruda, a single product central to its growth.
Growth drivers differ in kind. Biogen's story is built on near-term clinical readouts and acquisitions that could reshape its pipeline, while Merck's rests on sustaining Keytruda, expanding cardiometabolic and vaccine launches, and building a next-generation portfolio. Risk profiles also diverge: Biogen carries binary clinical-trial risk and MS erosion, whereas Merck faces legal rulings, generic pressure, and China-related vaccine weakness. On valuation, Merck's elevated P/E ratio reflects depressed current earnings, while Biogen's lower multiple reflects a turnaround still in progress.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely view BIIB as the more favorable near-term candidate among the two. Biogen's recent price action has been trending with greater consistency, it sits near highs with a defined catalyst calendar ahead, and its lower beta suggests steadier momentum relative to its own history. By contrast, Merck's recent pullback, legal overhang, and rising short interest introduce more near-term uncertainty even amid a strong longer-term trend. This is a probabilistic assessment rather than a definitive prediction, and relative conditions could shift as new earnings and clinical data emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Buy and MRK is a StrongBuy.
BIIB's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for BIIB turned positive on October 13, 2026. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in 41 of 59 cases over the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BIIB as a result. In 52 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 166 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
The Aroon Indicator entered an Uptrend today. In 122 of 197 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
BIIB broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.978) is normal, around the industry mean (-2.810). P/E Ratio (44.412) is within average values for comparable stocks, (21.105). Projected Growth (PEG Ratio) (2.357) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
MRK's Stochastic Oscillator dives into oversold zone
The Stochastic Oscillator for MRK moved into oversold territory on October 26, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +4.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 192 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRK as a result. In 41 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 48%.
The Moving Average Convergence Divergence Histogram (MACD) for MRK turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 28 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 55%.
MRK moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MRK crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 31 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.547) is normal, around the industry mean (-2.810). MRK's P/E Ratio (115.294) is considerably higher than the industry average of (21.105). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.040) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
BIIB | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 23 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 89 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 31 | |
SMR RATING 1..100 | 84 | 79 | |
PRICE GROWTH RATING 1..100 | 6 | 39 | |
P/E GROWTH RATING 1..100 | 3 | 1 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BIIB's Valuation (78) in the Biotechnology industry is in the same range as MRK (89) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to MRK’s over the last 12 months.
MRK's Profit vs Risk Rating (31) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that MRK’s stock grew significantly faster than BIIB’s over the last 12 months.
MRK's SMR Rating (79) in the Pharmaceuticals Major industry is in the same range as BIIB (84) in the Biotechnology industry. This means that MRK’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's Price Growth Rating (6) in the Biotechnology industry is somewhat better than the same rating for MRK (39) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew somewhat faster than MRK’s over the last 12 months.
MRK's P/E Growth Rating (1) in the Pharmaceuticals Major industry is in the same range as BIIB (3) in the Biotechnology industry. This means that MRK’s stock grew similarly to BIIB’s over the last 12 months.
| BIIB | MRK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 75% | N/A |
| Stochastic ODDS (%) | 1 day ago 67% | 1 day ago 69% |
| Momentum ODDS (%) | 1 day ago 61% | 1 day ago 48% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 55% |
| TrendWeek ODDS (%) | 1 day ago 61% | 1 day ago 49% |
| TrendMonth ODDS (%) | 1 day ago 65% | 1 day ago 43% |
| Advances ODDS (%) | 7 days ago 59% | 6 days ago 57% |
| Declines ODDS (%) | 19 days ago 68% | 1 day ago 51% |
| BollingerBands ODDS (%) | 1 day ago 68% | 1 day ago 69% |
| Aroon ODDS (%) | 1 day ago 62% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 2 FA rating(s) are green while MRK’s FA Score has 2 green FA rating(s).
- BIIB’s FA Score: 2 green, 3 red.
- MRK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 4 TA indicator(s) are bullish while MRK’s TA Score has 3 bullish TA indicator(s).
- BIIB’s TA Score: 4 bullish, 4 bearish.
- MRK’s TA Score: 3 bullish, 5 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +8.04% price change this week, while MRK (@Pharmaceuticals: Major) price change was -2.10% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.59%. For the same industry, the average monthly price growth was -5.20%, and the average quarterly price growth was +5.45%.
Reported Earning Dates
BIIB is expected to report earnings on Oct 28, 2026.
MRK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.59% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement